ANIK
Anika Therapeutics, Inc.·Healthcare
14.76
3.022%(−0.46)
Market ClosedLast Updated: — ET
52W L: $7.8752W H: $15.48
ANIK NEWS
gurufocus.com
10h ago
Is Anika Therapeutics Inc (ANIK) a Bargain After 3.1% Drop? GF Value Says Undervalued
On April 10, 2026, Anika Therapeutics Inc (ANIK) shares fell 3.1% to a current price of $14.76. This price is within a 52-week range of $7.87 to $15.48, indicat
globenewswire.com
Apr 3
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
benzinga.com
Mar 4
Top 2 Health Care Stocks That May Crash This Quarter
As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
seekingalpha.com
Feb 26
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
zacks.com
Feb 26
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.03 per share a year ago.
globenewswire.com
Feb 26
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025.
